XML 32 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Non-controlling Interest
9 Months Ended
Sep. 30, 2025
Noncontrolling Interest [Abstract]  
Non-controlling Interest

Note O – Non-controlling Interest

 

Non-controlling interest recorded in our condensed consolidated financial statements as of September 30, 2025 and December 31, 2024, relates to the following approximate interests in certain consolidated subsidiaries, which we do not own.

 

 

September 30, 2025

 

 

December 31, 2024

 

MiNK Therapeutics, Inc.

 

 

0

%

 

 

45

%

SaponiQx, Inc.

 

 

30

%

 

 

30

%

Changes in non-controlling interest for the periods ended September 30, 2025 and December 31, 2024, were as follows (in thousands):

 

 

September 30, 2025

 

 

December 31, 2024

 

Beginning balance

 

$

19,956

 

 

$

11,949

 

 

 

 

 

 

 

 

Net loss attributable to non-controlling interest

 

 

(3,164

)

 

 

(5,059

)

 

 

 

 

 

 

 

Other items:

 

 

 

 

 

 

Deconsolidation of a subsidiary

 

 

(25,037

)

 

 

 

Sale of subsidiary shares in private placement

 

 

 

 

 

10,234

 

Issuance of subsidiary shares for employee stock purchase plan and exercise of options

 

 

1

 

 

 

20

 

Subsidiary share-based compensation

 

 

1,513

 

 

 

2,812

 

Total other items

 

 

(23,523

)

 

 

13,066

 

 

 

 

 

 

 

 

Ending balance

 

$

(6,731

)

 

$

19,956

 

Deconsolidation of a subsidiary

In the quarter ended September 30, 2025, we deconsolidated MiNK and derecognized the associated non-controlling interest balance.

Sale of subsidiary shares in private placement

In May 2024, MiNK entered into a Stock Purchase Agreement with a certain investor (the “Purchaser”), pursuant to which MiNK issued and sold an aggregate of 464,000 shares of its Common Stock (the “MiNK Common Shares”), at a purchase price of $12.50 per share. The aggregate purchase price paid by the Purchaser for the MiNK Common Shares was approximately $5.8 million, net of offering expenses.